Truvestments Capital’s Biogen BIIB Stock Holding History

Truvestments Capital’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.48K	Sell	19 -14	-42%	-$2.58K	﹤0.01%	941
2025 Q4	$5.81K	Hold	33	–	–	﹤0.01%	781
2025 Q3	$4.66K	Sell	33 -35	-51%	-$4.73K	﹤0.01%	836
2025 Q2	$8.57K	Hold	68	–	–	﹤0.01%	663
2025 Q1	$9.3K	Sell	68 -8	-11%	-$1.14K	﹤0.01%	669
2024 Q4	$11.6K	Buy	76 +40	+111%	+$6.75K	﹤0.01%	581
2024 Q3	$6.98K	Buy	+36	New	+$7.53K	﹤0.01%	639
2024 Q1	–	Sell	-55	Closed	-$14.2K	–	742
2023 Q4	$14.2K	Hold	55	–	–	0.01%	486
2023 Q3	$14.1K	Hold	55	–	–	0.01%	421
2023 Q2	$15.7K	Buy	+55	New	+$16.4K	0.01%	408
2023 Q1	–	Sell	-12	Closed	-$3.32K	–	699
2022 Q4	$3.32K	Hold	12	–	–	﹤0.01%	621
2022 Q3	$3K	Hold	12	–	–	﹤0.01%	505
2022 Q2	$2K	Buy	+12	New	+$2.45K	﹤0.01%	551
2019 Q3	–	Sell	-200	Closed	-$47K	–	696
2019 Q2	$47K	Hold	200	–	–	0.03%	289
2019 Q1	$47K	Buy	+200	New	+$63K	0.04%	286
2018 Q3	$71K	Buy	+200	New	+$68.9K	0.03%	312

Other funds holding BIIB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Truvestments Capital's BIIB Position: Q1 2026 in Review

Truvestments Capital reduced its Biogen (BIIB) stake by 42% in Q1 2026, selling an estimated $2.58K and leaving 19 shares worth $3.48K. The position accounts for ﹤0.01% of the portfolio, ranked #941.

Truvestments Capital first reported a position in BIIB in Q3 2018 and has held it in 16 quarters since. The position peaked at $71K in Q3 2018. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

Truvestments Capital held 19 shares of Biogen worth $3.48K as of Q1 2026.
Truvestments Capital sold 14 Biogen shares in Q1 2026, an estimated $2.58K.
Biogen made up ﹤0.01% of Truvestments Capital's portfolio in Q1 2026, its #941 holding.
Truvestments Capital first reported a position in Biogen in Q3 2018 and has held it in 16 quarters since.
Truvestments Capital's Biogen position peaked at $71K in Q3 2018.
1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Truvestments Capital's 13F filing for Q1 2026, filed 13 May 2026.